# US 2004/0001868 A1 · Composition and method for treatment of otitis media

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0001868 A1
- Document ID: US20040001868A1
- Status: Published application
- Kind: A1
- Application number: 10/608,166
- Filed: 2003-06-27
- Published: 2004-01-01
- Earliest claimed: 1999-11-28
- Inventors: Alan J. Mautone
- Web page: https://patentgrep.com/patent/US20040001868A1

## CPC

- A61K 9/1274: Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
- A61K 9/0043: {Nose}
- A61K 9/0046: {Ear}
- A61K 9/12: Aerosols; Foams {(A61K9/0043, A61K9/0056, A61K9/006, A61K9/0073 take precedence; spray-films A61K9/7015)}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61P 27/16: Otologicals
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K 9/008: {comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

A process, composition and method for increasing and enhancing mammalian eustachian tube lumen patency and pressure equalization performance is disclosed wherein an aerosolized mixture of lipid crystals comprised of a mixture of one or more lipids surfactants and one or more spreading agents selected from the group consisting of sterols, lipids, fatty acids, cholesteryl esters, phospholipids, carbohydrates, and proteins, in powder form, and one or more propellants, in which the lipid surfactants and spreading agents are not soluble, are administered through a mammalian airway orifice. Upon administration, the propellant(s) are evaporated from the mixture and the lipid crystals are deposited within a subject mammalian eustachian tube whereupon said lipid crystals come into contact with lumen surfaces of the tube forming an amorphous spread film thereupon substantially decreasing the opening pressure of the lumen. In a second preferred embodiment, a therapeutically active agent effective in the treatment of otitis media is added to the mixture of lipid crystals and upon administration of said aerosol mixture, the amorphous spread film formed thereby carries said therapeutically active agent through the eustachian tube to the tissues of the middle ear. In an alternate preferred embodiment, the afore-mentioned reduction of surface tension and delivery of therapeutically active agents is provided by a mixture of lipid crystals comprised of surfactant(s), therapeutically active agents and a propellant in which such other components are not soluble.

## Claims

### Claim 1

A process for preparing a eustachian tube lumen patency and performance enhancing medicament comprising:
combining one or more lipid surfactants, one or more spreading agents and one or more propellants to form a mixture, said lipids and said spreading agents being selected from the group consisting of sterols, lipids, fatty acids, cholesteryl esters, phospholipids, carbohydrates, and proteins, all in powder form, wherein said lipids and said spreading agents are insoluble in the propellants and said lipid surfactants are selected to be present in an amount effective in reducing surface tension of an air/liquid interface resident upon epithelial tissue lining the lumen of the eustachian tube and said spreading agents are selected to be present in an amount effective in distributing said surfactant within said lumen when said propellants are evaporated from said mixture to form a mixture of lipid crystals for use as the medicament.

### Claim 2 (depends on 1)

The process of claim 1 wherein said lipid surfactant is selected to be present in an amount of from about 99.99 to about 50 weight percent and wherein said spreading agent is selected to be present in an amount of from about 50 to about 0.01 weight percent.

### Claim 3 (depends on 1)

The process of claim 1 wherein said lipid surfactant is selected to be present in an amount of from about 80 to about 99.5 weight percent and wherein said spreading agent is selected to be present in an amount of from about 20 to about 0.5 weight percent.

### Claim 4 (depends on 1)

The process of claim 1 further comprising bottling said mixture within a metered dose device

### Claim 5 (depends on 1)

The process of claim 1 wherein the sterols are selected from the group consisting of cholesterol, ergosterol, cholecalciferol and mixtures thereof.

### Claim 6 (depends on 1)

The process of claim 1 wherein the fatty acids are selected from the group consisting of palmitic acid, oleic acid and mixtures thereof.

### Claim 7 (depends on 1)

The process of claim 1 wherein the lipids are selected from the group consisting of phospholipids, neutral lipids and mixtures thereof.

### Claim 8 (depends on 7)

The process of claim 7 wherein the phospholipids are selected to be any of a class known as phosphatidylcholines.

### Claim 9 (depends on 8)

The process of claim 8 wherein the phosphatidylcholine is selected to be any fully saturated diacyl phosphatidylcholine.

### Claim 10 (depends on 9)

The process of claim 9 wherein the fully saturated diacyl phosphatidylcholine is selected to be 1,2 dipalmitoyl phosphatidylcholine.

### Claim 11 (depends on 7)

The process of claim 7 wherein the phospholipid is selected from the group consisting of diacylphosphatidylglycerol, diacylphosphatidylethanolamime, diacylphosphatidylserine, diacylphosphatidylinositol, sphingomelin, Cardiolipin, lysophospholipid, plasmalogen, diether phosphonolipid, dialkylphospholipid, and mixtures thereof.

### Claim 12 (depends on 1)

The process of claim 1 wherein the carbohydrates are selected from the group consisting of glucose, fructose, galactose, pneumogalactan, dextrose and mixtures thereof.

### Claim 13 (depends on 1)

The process of claim 1 wherein the protein is selected from the group consisting of albumin and pulmonary surfactant specific proteins A, B, C, D and mixtures thereof.

### Claim 14 (depends on 1)

The process of claim 1 wherein the cholesteryl ester is selected from the group consisting of cholesteryl palmitate, cholesteryl oleate, cholesteryl stearate and mixtures thereof.

### Claim 15 (depends on 1)

The process of claim 1 wherein the propellants are selected to be fluorocarbons.

### Claim 16 (depends on 15)

The process of claim 15 wherein the fluorocarbon is selected from the group consisting of chlorofluorocarbon, hydrofluorocarbon and mixtures thereof.

### Claim 17 (depends on 1)

The process of claim 1 wherein the propellant is selected to be carbon dioxide.

### Claim 18 (depends on 1)

The process of claim 1 wherein the propellant is selected to be any pharmaceutical grade hypo-allergenic propellant in which the at least one surfactant and spreading agent are not soluble.

### Claim 19 (depends on 1)

The process of claim 1 wherein 95 percent of said crystals demonstrate a particle size no greater than 4 microns in diameter.

### Claim 20

A process for preparing an otitis media medicament comprising:
combining at least one lipid surfactant, at least one spreading agents, at least one therapeutically active agents effective in the treatment of otitis media and at least one propellants to form a mixture, said lipids and said spreading agents being selected from the group consisting of sterols, lipids, fatty acids, cholesteryl esters, phospholipids, carbohydrates, and proteins all in powder form, wherein said lipids, said spreading agents and said therapeutically active agents are insoluble in the propellants and said lipids are selected to be present in an amount effective in lowering surface tension of an air/liquid interface resident upon epithelial tissues lining mammalian eustachian tube and middle ear and said spreading agents being present in an amount effective in distributing said surfactant within said lining of the lumen and middle ear when said propellants are evaporated from said mixture to form a mixture of lipid crystals combined with said therapeutic agents for use as the medicament.

### Claim 21 (depends on 20)

The process of claim 20 wherein said lipid surfactant is selected to be present in an amount of from about 99.99 to about 50 weight percent and wherein said spreading agent is selected to be present in an amount of from about 50 to about 0.01 weight percent.

### Claim 22 (depends on 20)

The process of claim 20 wherein said lipid surfactant is selected to be present in an amount of from about 80 to about 99.5 weight percent and wherein said spreading agent is selected to be present in an amount of from about 20 to about 0.5 weight percent.

### Claim 23 (depends on 20)

The process of claim 20 further comprising bottling said mixture within a metered dose device

### Claim 24 (depends on 20)

The process of claim 20 wherein the sterols are selected from the group consisting of cholesterol, ergosterol, cholecalciferol and mixtures thereof.

### Claim 25 (depends on 20)

The process of claim 20 wherein the fatty acids are selected from the group consisting of palmitic acid, oleic acid and mixtures thereof.

### Claim 26 (depends on 20)

The process of claim 20 wherein the lipids are selected from the group consisting of phospholipids, neutral lipids and mixtures thereof.

### Claim 27 (depends on 26)

The process of claim 26 wherein the phospholipids are selected to be any of a class known as phosphatidylcholines.

### Claim 28 (depends on 27)

The process of claim 27 wherein the phosphatidylcholine is selected to be any fully saturated diacyl phosphatidylcholine.

### Claim 29 (depends on 28)

The process of claim 28 wherein the fully saturated diacyl phosphatidylcholine is selected to be 1,2 dipalmitoyl phosphatidylcholine.

### Claim 30 (depends on 26)

The process of claim 26 wherein the phospholipid is selected from the group consisting of diacylphosphatidylglycerol, diacylphosphatidylethanolamime, diacylphosphatidylserine, diacylphosphatidylinositol, sphingomelin, Cardiolipin, lysophospholipid, plasmalogen, diether phosphonolipid, dialkylphospholipid, and mixtures thereof.

### Claim 31 (depends on 20)

The process of claim 20 wherein the carbohydrates are selected from the group consisting of glucose, fructose, galactose, pneumogalactan, dextrose and mixtures thereof.

### Claim 32 (depends on 20)

The process of claim 20 wherein the protein is selected from the group consisting of albumin and pulmonary surfactant specific proteins A, B, C, D and mixtures thereof.

### Claim 33 (depends on 20)

The process of claim 20 wherein the cholesteryl ester is selected from the group consisting of cholesteryl palmitate, cholesteryl oleate, cholesteryl stearate and mixtures thereof.

### Claim 34 (depends on 20)

The process of claim 20 wherein said therapeutically active agent is selected from the group consisting of anti-inflammatory, antibiotic, decongestant and gene therapy agents.

### Claim 35 (depends on 34)

The process of claim 34 wherein the anti-inflammatory agent is selected to be betamethasone.

### Claim 36 (depends on 34)

The process of claim 34 wherein said antibiotic is selected from the group consisting of erythromycin, amoxicillin, zythromax, Augmentin and mixtures thereof.

### Claim 37 (depends on 34)

The process of claim 34 wherein the decongestant is selected to be phenylephrine.

### Claim 38 (depends on 20)

The process of claim 20 wherein the propellants are selected to be fluorocarbons.

### Claim 39 (depends on 38)

The process of claim 38 wherein the fluorocarbon is selected from the group consisting of chlorofluorocarbons, hydrofluorocarbons and mixtures thereof.

### Claim 40 (depends on 20)

The process of claim 20 wherein the propellant is selected to be carbon dioxide.

### Claim 41 (depends on 20)

The process of claim 20 wherein the propellant is selected to be any hypo-allergenic, pharmaceutical grade propellant in which the neither the surfactant, spreading agent or therapeutically active agent are soluble.

### Claim 42 (depends on 20)

The process of claim 20 wherein 95 percent of said crystals demonstrate a particle size no greater than 4 microns in diameter.

### Claim 43

A process for preparing an otitis media medicament comprising:
combining at least one lipid surfactant, at least one therapeutically active agent effective in the treatment of otitis media and at least one propellants to form a mixture, said lipid surfactants being selected from the group consisting of sterols, lipids, fatty acids, cholesteryl esters, phospholipids, carbohydrates, and proteins all in powder form, wherein said lipids and said therapeutically active agents are insoluble in the propellants and said lipids are selected to be present in an amount effective in lowering surface tension of an air/liquid interface resident upon epithelium lining said eustachian tube and middle ear and effective in distributing said surfactant within said lining of the lumen and middle ear when said propellants are evaporated to form an aerosolized mixture of lipid crystals combined with said therapeutic agents for use as the medicament.

### Claim 44 (depends on 43)

The process of claim 43 wherein said lipid surfactant is selected to be present in an amount of from about 99.99 to about 50 weight percent and wherein said therapeutically active agent is selected to be present in an amount of from about 50 to about 0.01 weight percent.

### Claim 45 (depends on 43)

The process of claim 43 wherein said lipid surfactant is selected to be present in an amount of from about 80 to about 99.5 weight percent and wherein said therapeutically active agent is selected to be present in an amount of from about 20 to about 0.5 weight percent.

### Claim 46 (depends on 43)

The process of claim 43 further comprising bottling said mixture within a metered dose administration device.

### Claim 47 (depends on 43)

The process of claim 43 wherein the sterols are selected from the group consisting of cholesterol, ergosterol, cholecalciferol and mixtures thereof.

### Claim 48 (depends on 43)

The process of claim 43 wherein the fatty acids are selected from the group consisting of palmitic acid, oleic acid and mixtures thereof.

### Claim 49 (depends on 43)

The process of claim 43 wherein the lipids are selected from the group consisting of phospholipids, neutral lipids and mixtures thereof.

### Claim 50 (depends on 49)

The process of claim 49 wherein the phospholipids are any of a class known as phosphatidylcholines.

### Claim 51 (depends on 50)

The process of claim 50 wherein the phosphatidylcholine is any fully saturated diacyl phosphatidylcholine.

### Claim 52 (depends on 51)

The process of claim 51 wherein the fully saturated diacyl phosphatidylcholine is 1,2 dipalmitoyl phosphatidylcholine.

### Claim 53 (depends on 49)

The process of claim 49 wherein the phospholipid is selected from the group consisting of diacylphosphatidylglycerol, diacylphosphatidylethanolamime, diacylphosphatidylserine, diacylphosphatidylinositol, sphingomelin, Cardiolipin, lysophospholipid, plasmalogen, diether phosphonolipid, dialkylphospholipid, and mixtures thereof.

### Claim 54 (depends on 43)

The process of claim 43 wherein the carbohydrates are selected from the group consisting of glucose, fructose, galactose, pneumogalactan, dextrose and mixtures thereof.

### Claim 55 (depends on 43)

The process of claim 43 wherein the protein is selected from the group consisting of albumin and pulmonary surfactant specific proteins A, B, C, D and mixtures thereof.

### Claim 56 (depends on 43)

The process of claim 43 wherein the cholesteryl ester is selected from the group consisting of cholesteryl palmitate, cholesteryl oleate, cholesteryl stearate and mixtures thereof.

### Claim 57 (depends on 43)

The process of claim 43 wherein said therapeutically active agent is selected from the group consisting of anti-inflammatory, antibiotic, decongestant and gene therapy agents.

### Claim 58 (depends on 57)

The process of claim 57 wherein said anti-inflammatory agent is betamethasone.

### Claim 59 (depends on 57)

The process of claim 57 wherein said antibioitic is selected from the group consisting of erythromycin, amoxicillin, zythromax and Augmentin.

### Claim 60 (depends on 57)

The process of claim 57 wherein said decongestant is phenylephrine.

### Claim 61 (depends on 43)

The process of claim 43 wherein the propellants are fluorocarbons.

### Claim 62 (depends on 61)

The process of claim 61 wherein the fluorocarbon is selected from the group consisting of chlorofluorocarbon, hydrofluorocarbon and mixtures thereof.

### Claim 63 (depends on 43)

The process of claim 43 wherein the propellant is selected to be carbon dioxide.

### Claim 64 (depends on 43)

The process of claim 43 wherein the propellant is selected to be any pharmaceutical grade, hypo-allergenic propellant in which neither the at least one surfactant or therapeutic agent are not soluble.
